Request Demo
Last update 17 Apr 2025
ASP-7373
Last update 17 Apr 2025
Overview
Basic Info
Drug Type Prophylactic vaccine |
Synonyms 組換えインフルエンザHAワクチン（H5N1）, ASP-7373, UMN-0501 |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
5
Clinical Trials associated with ASP-7373NCT01612000
Phase 2 Observer-Blind, Randomized Trial to Evaluate the Immunogenicity and Safety of PanBlok at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With PanBlok Without Adjuvant in Healthy Adults Aged 18 to 49 Years
NCT01450579
Phase II Study of ASP7373 Evaluation of Immunogenicity and Safety of ASP7373 in Healthy Adults
NCT01147068
A Two-Part Placebo-Controlled Evaluation of the Safety and Immunogenicity of an A/Indonesia/5/05 Recombinant Hemagglutinin Influenza H5N1 Vaccine With and Without Glucopyranosyl Lipid A (GLA-SE) in Healthy Adults 18-49
100 Clinical Results associated with ASP-7373
Login to view more data
100 Translational Medicine associated with ASP-7373
Login to view more data
100 Patents (Medical) associated with ASP-7373
Login to view more data
100 Deals associated with ASP-7373
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Influenza, Human | Phase 2 | Japan | 01 Oct 2009 | |
| Influenza A virus infection | Phase 1 | Australia | 12 Oct 2017 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 341 | rHA adjuvant+PanBlok (PanBlok 15µg in 2% SE) | lzoegkxwuq = hwrjxzdaby dsgqubjvcp (cunlclsvvk, leyhcgabyh - mtrcgvtskr) View more | - | 25 Nov 2015 | ||
rHA adjuvant+PanBlok (PanBlok 3.8µg in 2% SE) | lzoegkxwuq = hgvzrixlwi dsgqubjvcp (cunlclsvvk, hesssjistl - ojqirfhguf) View more | ||||||
Phase 1/2 | 392 | (Placebo) | gwdjgrgxya = ijpdvduypj xogltykhar (atqdrrikdw, zjlsbjcnxe - kwimoaesmy) View more | - | 26 Nov 2012 | ||
(PanBlok 135µg No Adjuvant) | gwdjgrgxya = ngzshnuxqw xogltykhar (atqdrrikdw, aocvieayau - eserkgrfmn) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free